Immuneering (NASDAQ:IMRX) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Immuneering (NASDAQ:IMRX) from a hold rating to a sell rating in a research note published on Monday morning.

IMRX has been the subject of several other reports. Cantor Fitzgerald began coverage on shares of Immuneering in a research note on Wednesday, July 8th. They set an “overweight” rating and a $17.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a research report on Wednesday, June 24th. Oppenheimer reiterated an “outperform” rating on shares of Immuneering in a report on Monday, June 1st. Finally, Chardan Capital reissued a “buy” rating and set a $20.00 price target on shares of Immuneering in a research report on Tuesday, May 19th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Immuneering presently has an average rating of “Moderate Buy” and an average target price of $17.57.

Immuneering Stock Performance

IMRX opened at $4.29 on Monday. The company’s 50 day simple moving average is $4.81 and its 200 day simple moving average is $5.10. Immuneering has a 1 year low of $2.90 and a 1 year high of $10.08. The stock has a market capitalization of $277.56 million, a PE ratio of -3.67 and a beta of 0.41.

Immuneering (NASDAQ:IMRX) last released its earnings results on Friday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.09. As a group, sell-side analysts expect that Immuneering will post -1.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of IMRX. Jane Street Group LLC acquired a new stake in shares of Immuneering in the first quarter worth $32,000. Geode Capital Management LLC raised its stake in shares of Immuneering by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock valued at $776,000 after acquiring an additional 4,458 shares during the period. XTX Topco Ltd acquired a new position in shares of Immuneering during the 2nd quarter valued at $90,000. Bridgeway Capital Management LLC lifted its holdings in shares of Immuneering by 57.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 95,449 shares of the company’s stock valued at $322,000 after acquiring an additional 35,000 shares in the last quarter. Finally, Corient Private Wealth LLC purchased a new stake in Immuneering during the 2nd quarter worth $215,000. 67.65% of the stock is owned by institutional investors and hedge funds.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.